Featured Research

from universities, journals, and other organizations

Promising Indiana University Lung Cancer Trial Enters New Phase

Date:
January 15, 2002
Source:
Indiana University
Summary:
The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results. The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The Indiana University School of Medicine is now recruiting patients for the second phase of a lung cancer trial that has shown promising results.

Related Articles


The procedure, extracranial stereotactic radioablation, uses three-dimensional imaging and high doses of radiation to more precisely target and kill cancer cells in the lung. It uses treatment concepts similar to those used in Gamma Knife radiosurgery, a non-invasive technique shown to be effective in treating brain tumors.

The procedure uses a 3-D computer generated grid system to more precisely map the location where therapy is directed. The patient is positioned in a specially fitted, lightweight body frame that limits mobility to ensure the precision of photon beams aimed at the tumor. "One advantage of the combined technology is that the risk of damaging healthy tissue despite such potent doses of radiation is reduced in comparison to conventional radiation."

"The results of the first phase were very encouraging and somewhat surprising," says Robert D. Timmerman, M.D., assistant professor of radiation oncology and the trial's principal investigator at the Indiana University Cancer Center. "We thought patients only would be able to tolerate lower doses since frail patients typically can't tolerate such rigorous treatment. To our surprise, we were able to increase dose levels without prohibitive toxicity."

This latest phase seeks to enroll 35 patients with early stage, non-small cell lung cancer whose tumors have not spread to lymph nodes or beyond and who have health conditions such as emphysema, severe heart disease, diabetes or a history of strokes, therefore making them poor candidates for surgery.

"Using a potent dose with assurance of reasonable safety to patients, we now want to measure the rate of controlling lung cancer and measure the patient's overall disease-free survival," Dr. Timmerman says.

Early stage lung cancer traditionally is treated with surgery, conventional radiation, or both. There is a 60 percent to 70 percent cure rate for early stage lung cancer in patients undergoing surgery, and a 20 percent to 30 percent cure rate for those treated with conventional radiation, which usually involves up to six weeks of daily radiation treatments.

In contrast, Phase 2 of this IU lung cancer trial delivers the entire treatment in three visits.

"We're optimistic this new therapy will bridge this large disparity giving patients a better chance of survival and a cure," notes Dr. Timmerman.


Story Source:

The above story is based on materials provided by Indiana University. Note: Materials may be edited for content and length.


Cite This Page:

Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. ScienceDaily, 15 January 2002. <www.sciencedaily.com/releases/2002/01/020115074910.htm>.
Indiana University. (2002, January 15). Promising Indiana University Lung Cancer Trial Enters New Phase. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2002/01/020115074910.htm
Indiana University. "Promising Indiana University Lung Cancer Trial Enters New Phase." ScienceDaily. www.sciencedaily.com/releases/2002/01/020115074910.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins